Financial Data

FY2017 Result

  • Due to the growth of Halaven (anticancer agent), Lenvima (anticancer agent, product name for use in the treatment of renal cell carcinoma in Europe: Kisplyx), Humira (fully-human anti-TNF-α monoclonal antibody) and Fycompa (antiepileptic agent) in addition to the receipt of lump-sum payments per the strategic collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, the Group’s revenue finished overall up 11.3% year on year.
  • By segment, revenue from the Group’s Japan pharmaceutical business increased, and the China, EMEA, and Asia and Latin America pharmaceutical businesses each experienced double digit growth. By product, combined revenue from all four global brands soared by 25.4% year on year. This included Halaven, Lenvima, Fycompa, and BELVIQ (antiobesity agent).
  • Operating profit totaled up 30.7% year on year as increased gross profit from the increase in revenue outweighed the aggressive R&D investment in Alzheimer's disease projects, such as E2609 (beta secretase cleaving enzyme [BACE] inhibitor, generic name: elenbecestat), and oncology projects.
  • Profit for the year came to up 28.8% year on year, while profit for the year attributable to owners of the parent came to up 31.7% year on year.